-
1
A meta-analysis of 10 comparative studies found similar csPCa detection performance for AI systems and experienced radiologists, with sROC AUCs of 0.88 and 0.85, respectively.
-
2
Biological heterogeneity, MRI acquisition limits, observer variability, and biopsy sampling error create irreducible uncertainty that constrains achievable diagnostic performance.
-
3
AUCs approaching 1.0 require scrutiny of intended-use populations, endpoint definitions, cohort selection, and reference-standard quality.
-
4
Biopsy is an imperfect reference standard because it samples only part of the prostate and can miss lesions or misgrade cancer; prostatectomy pathology is more comprehensive but selectively available.
-
5
The PI-RADS Steering Committee requirements, CLAIM checklist, and TRIPOD + AI guidelines provide standards for evaluating and reporting prostate MRI AI studies.
